bsHexAb

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NamebsHexAb
Drug Alias Name22*-(19)-(19)22*-(20)-(20)CK-22-(20)-(20)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized +[4] 
Mechanisms of ActionB-lymphocyte antigen CD20 inhibitorsCD226 antigen blockers
TargetsCD226 antigenB-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesImmunomedics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesImmunomedics Inc
Active IndicationsN/A
Inactive IndicationsLymphoma

Other Information

ATC CodeN/A
Related LinksN/A